Dose–response higher proportion of fibrosis improvement without worsening of MASH (39 and 41% vs. 20% for placebo), and of MASH resolution without worsening fibrosis (47 and 76% vs. 15% for placebo)Improvement of LFC, weight, insulin sensitivity and lipid profile. Here, INS is linked to metabolic dysfunction-associated steatohepatitis.